Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03205995 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome
A Phase 3 study, sponsored by Omeros Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 6
- Enrollment target
NCT03205995: Clinical Trial Phase 3 study, sponsored by Omeros Corporation.
NCT03205995 is a Phase 3 study that was terminated before completion, run by Omeros Corporation. The registered enrollment target is 6 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03205995, a Phase 3 study, was terminated before completion, sponsored by Omeros Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the platelet count change from baseline and safety of OMS721 (narsoplimab) in adults and adolescents with atypical hemolytic uremic syndrome (aHUS). The study will also evaluate pharmacokinetics (PK), pharmacodynamics (PD), and anti-drug antibody response (ADA).
Primary Outcome
The primary outcome to be measured is platelet count change from baseline.
Interventions
- BIOLOGICAL OMS721 (narsoplimab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-05-02 |
| Est. Completion | 2021-02-02 |
| Phase | Phase 3 |
Why NCT03205995 stopped before completion
NCT03205995 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which OMS721 (narsoplimab) is the first listed.
NCT03205995 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03205995 about?
NCT03205995 is a clinical study titled "Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome". The purpose of this study is to evaluate the platelet count change from baseline and safety of OMS721 (narsoplimab) in adults and adolescents with atypical hemolytic uremic syndrome (aHUS). The study will also evaluate pharmacokinetics (PK), pharmacodynamics (PD), and anti-drug antibody response (AD...
What is the current status of trial NCT03205995?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 6 participants. The study started on 2018-05-02. Estimated completion is 2021-02-02.
What interventions are being tested in trial NCT03205995?
The interventions under investigation include: OMS721 (narsoplimab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03205995?
This trial is sponsored by Omeros Corporation, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03205995's enrollment target sits among peer trials
6 1995th of 2000 higher than 4 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI